According to LiveReport's big data, as of the close on July 22nd, the top 10 companies in terms of market value among Hong Kong's 18A Biotech stocks were BeiGene (6160.HK), Innovent Biologics (1801.HK), KangFang Biotech (9926.HK), Ceren Bio-Tech-B (6990.HK), Regeneron (9688.HK), Junshi Biosciences (1877.HK), Fosun Pharma (2696.HK), Yasheng Medicine-B (6855.HK), CanSino-B (2162.HK) and Rongchang Biotech (9995.HK). All 10 companies are clients of Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan').
Top 10 Market Values of Hong Kong's 18A Biotech Stocks
Baiji Sinovation
688235.SH, 6160.HK, BGNE.US
Baiji Shenzhou is a global biotech company at the commercial stage, focusing on research, development, production, and commercialization of innovative drugs. It is the world's first biotech company to be listed on the New York Stock Exchange, Hong Kong Stock Exchange, and Shanghai Stock Exchange. The company practices the development strategy of 'rooted in China, looking globally', actively seizing the development opportunities brought about by China's medical regulatory reforms for the biopharmaceutical industry, establishing internal key capabilities, and gradually growing into a comprehensive global biotech company with early drug discovery, clinical research, large-scale high-quality drug production, and science-based commercialization capabilities. The company's independently developed products currently on the market include: Zanubrutinib Capsules (Baiyueze®), Tislelizumab Injection (Baiszaan®), and Perampanel Capsules (Baihuize®).
🔗:
Innovent Biologics
1801.HK
"Starting with belief, achieving through action," developing high-quality biopharmaceuticals that are affordable for the common people is the mission and goal of Innovent Biologics. Innovent Biologics was established in 2011, dedicated to the research, development, production, and sales of innovative drugs for major diseases such as oncology, autoimmune diseases, metabolism, and ophthalmology. The company has already had 10 products approved for market launch: infliximab injection (Dabrucevimab), bevacizumab injection (Daurubicin), adalimumab injection (Sulimab), rituximab injection (Daratumab), perimetinib tablets (Dabraytinib), olaparib tablets (Nirrepalib), ramucirumab injection (Cimzia), selitinib capsules (Rutinib), ibrutinib injection (Fosunetum), and tolecalcetib injection (Sintilimab).
🔗:
Kangfang Biology
9926.HK
Kangfang Biotech is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative antibody new drugs with independent intellectual property rights, focusing on addressing unmet needs in oncology, autoimmune diseases, and other therapeutic areas. The company has built a unique end-to-end Kangfang All-round New Drug Research and Development Platform (ACE Platform), established a R&D innovation system centered on Tetrabody bispecific antibody development technology, antibody conjugation (ADC) technology platform, mRNA technology platform, and cell therapy technology, as well as an international-standard GMP production system and an advanced commercialization model. The company's currently marketed products include: PD-1 monoclonal antibody, Pemplituzumab Injection (Annikero®), PD-1/CTLA-4 bispecific antibody, Camdurilimab Injection (Kantana®), PD-1/VEGF bispecific antibody, and Ivosidenib Injection (Edafang®).
🔗:
Corumbato
6990.HK
CerenBio is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative drugs. Since its establishment in 2016, it has been committed to addressing medical needs in China and around the world. With integrated drug development capabilities and a comprehensive management system covering all key business functions, CerenBio is dedicated to internally developing differentiated treatment methods to support improving existing healthcare levels. As one of the pioneers and leading developers of antibody-drug conjugates (ADCs), CerenBio has accumulated over a decade of experience in ADC development and is one of the first biopharmaceutical companies in China and globally to establish an integrated ADC R&D platform OptiDC.
🔗:
ZaiDi Medical
9688.HK
Zai Lab is a patient-centered, commercial-stage innovative global biopharmaceutical company based in China and operating globally. It is committed to providing patients in China and around the world with best-in-class and first-in-class drugs for tumors, autoimmune diseases, infectious diseases, and central nervous system diseases. The company's currently marketed products include: niraparib (Zelira ®), tumor electric field therapy (Aipund ® and Aipuhua ®), rupatimib (Qingle ®), rupatimib (Okeyle ®), omadacitinobetaine mesylate (Newel ®), sulbactam sodium-duloxetine sodium (Dingyoule ®), and iguratimod (Vivagard ® and Viliagard ®).
🔗:
Junshi Biology
1877.HK, 688180.SH
Junshi Biosciences was established in December 2012 and is a biopharmaceutical company driven by innovation, dedicated to the discovery, development, and commercialization of innovative therapies. With its outstanding ability in innovative drug discovery, advanced biotechnology research and development, large-scale production technology across the entire industrial chain, and a highly promising portfolio of drugs under research, Junshi Biosciences has great potential in the treatment of tumor immunotherapy, as well as autoimmune system diseases, chronic metabolic diseases, neurological diseases, infectious diseases, and more. The company's currently marketed products include: Trimercept (Torybrel), Adalimumab (JunmaiKang), Deucumab Hydrobromide Tablets (MindeV), and Etsevimab.
🔗:
Fosun Pharma
2696.HK
Fosun Pharma (2696.HK) is an international innovative biopharmaceutical company dedicated to providing affordable high-quality biologics for patients worldwide. Its products cover areas such as oncology, autoimmune diseases, and ophthalmic diseases. Following the successful approval of the first biosimilar in China, Hanli Kang® (rituximab), the independently developed Chinese, US, and European biosimilar, Hanquyu® (trastuzumab, US trade name: HERCESSI®, European trade name: Zercepac®), Handa Yuan® (adalimumab), and Hambetai® (bevacizumab), innovative product Hanshuang® (sulimumab) has been approved for the treatment of microsatellite high instability (MSI-H) solid tumors, squamous non-small cell lung cancer, extensive-stage small cell lung cancer, and esophageal squamous cell carcinoma. It has become the world's first approved anti-PD-1 monoclonal antibody for first-line treatment of small cell lung cancer.
🔗:
Yasheng Medicine
6855.HK
Yasheng Medicine is a biopharmaceutical company based in China, targeting the global market. It is one of the earliest companies in China to start research and development of original innovative drugs, dedicated to developing innovative drugs in therapeutic areas such as oncology, hepatitis B, and aging-related diseases. Yasheng Medicine has an independently constructed protein-protein interaction targeted drug design platform, which is at the forefront of new drug research and development in the cell apoptosis pathway. The company has established a pipeline of 9 first-class small molecule new drug products that have entered clinical development, including inhibitors of key proteins in the apoptosis pathway such as Bcl-2, IAP, or MDM2-p53; and inhibitors targeting kinase mutants that appear in cancer treatment. The company's independently developed products currently on market include: Orelabrutinib (Nirvana ®).
🔗:
Conoya
2162.HK
Connaughty Biologics is a biotechnology company focused on developing innovative biologics in the fields of autoimmune and oncology treatments. Connaughty Biologics takes 'innovation and excellence' as its mission, continuously providing high-quality affordable innovative biopharmaceuticals for patients in China and around the world. Its vision is to address urgent clinical needs by establishing a high-tech company representing the world's advanced level in the research and development of innovative therapeutic antibodies. Naughty Biologics has independently developed over 30 innovative drugs, with 10 of them entering different stages of clinical research and development. Many are ranked first in China and among the top three in the world, including a world-first ADC new drug and two that have received support from the national '13th Five-Year Plan' major new drug innovation science and technology project.
🔗:
Rongchang Biology
9995.HK, 688331.SH
Rongchang Biotech is committed to discovering, developing, producing, and commercializing first-in-class and best-in-class biopharmaceuticals for major diseases such as autoimmune disorders, oncology, and ophthalmology. The company has currently launched products including Tislelizumab (Tislelizumab & Tislelizumab Injection) and Vedolizumab (Vedolizumab Injection). At present, there are dozens of innovative drugs in the company's pipeline that are in the research and development or commercialization stages. In addition to the two world-class new drugs Tislelizumab and Vedolizumab, another VEGF/FGF dual-target innovative fusion protein product RC28, which has the potential for being a First-in-class in the field of ophthalmic treatment, has entered Phase III clinical trials. Five drugs are in Phase I/II clinical trials, several are in IND preparation stages.
🔗:
*All the above company information is sourced from the official websites of the companies.
As a global growth consulting firm, Frost & Sullivan integrates 63 years of consulting experience from around the world. Over the past 26 years, it has dedicated itself to serving the booming Chinese market with a global perspective, helping clients accelerate their business growth and achieve benchmark positions in industry growth, innovation, and leadership. The health care industry is one of the core areas of focus for Frost & Sullivan.
Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging the global think tank resources of Frost & Sullivan and its cross-industry business development platform in Greater China, Frost & Sullivan has unique core advantages in investment and financing services for the life science industry. Frost & Sullivan has a wide range of corporate clients in China and has established a vast client network over the past 20 years, accumulating a wealth of project experience in various sub-sectors of life sciences. The types of projects include knowledge center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry advisory, clinical audit, fundraising writing), market research, market value management, and strategic consulting, etc. It also collaborates with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices, attracting widespread attention from investors.
As an industry advisor, Frost & Sullivan has become the preferred partner for healthcare companies seeking to list in Hong Kong and overseas with its exceptional services. According to publicly disclosed information from the Hong Kong Exchange, from 2015 to 2023, Frost & Sullivan maintained a leading position in the Hong Kong stock market's listed advisory segment for nine consecutive years, accounting for the largest proportion of listed companies in the sector. It is an absolute leader in serving healthcare companies seeking to list in Hong Kong. In addition, since the first batch of companies on the Sci-Tech Innovation Board (STAR Market) was listed in July 2019, Frost & Sullivan's reports have been widely cited in the prospectuses of leading STAR Market listed companies, accounting for a market share of up to 75%.
Since the Hong Kong Exchange implemented its listing reform in 2018, Hong Kong has become Asia's largest and the world's second-largest biotech financing center. The capital market plays a key role in biotech development and in transmitting positive social impacts.TradeGo, in collaboration with Frost & Sullivan's LeadLeo Research Institute, cloud technology companies, and other institutions, has successively released the 'Investment Activity Report on the Issuance of 18A Biotech Companies in Hong Kong', the 'White Paper on the Development of the 18A Biotech Industry in Hong Kong in 2023', and the 'Blue Paper on the Development of the 18A & Sci-Tech Innovation Board Biotech Industry in Hong Kong in 2023'.
On July 16, 2024, Frost & Sullivan, in collaboration with LeadLeo Research Institute, TradeGo, cloud technology, and the Organizing Committee of the 3rd Boao Forum on Global Health, officially released the '2024 Hong Kong Stock Exchange 18A Biotech Companies Issuance and Investment Activity Report' at the 3rd Boao Forum on Global Health. The report analyzes the layout and trends of the Hong Kong stock exchange's 18A biotech industry. Through systematic review, it is aimed at providing a more comprehensive and in-depth understanding of the Hong Kong stock exchange's 18A biotech sector for shareholders of companies planning to go public or already listed, capital market intermediaries, and market investors. It also offers research guidance for market valuation, pipeline assessment, capital dynamics, corporate strategy, and more.
In the future, Frost & Sullivan will continue to increase its investment and focus on the life sciences field, actively explore new service and business models, pay attention to policy changes and market demands in the life sciences sector, and provide clients with more professional and efficient consulting services. We hope to work with more healthcare enterprises to understand industry trends, seize development opportunities, jointly promote the prosperity and development of China's healthcare industry, and contribute to the cause of human health.
